CORONADO, Calif. — Despite recent advances in the treatment of cutaneous squamous cell carcinoma (SCC), a lack of consensus ...

Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, ...

More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur.

Race, age, and sex were predictors of survival in patients with SCC of the upper esophagus, highlighting the need to address disparities in esophageal SCC management.

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

THE proportion of people diagnosed with lung cancer who’ve never smoked is increasing, the World Health Organization (WHO) ...

Background: Despite undergoing surgery and chemoradiotherapy, patients with first primary lung cancer (FPLC) remain at risk for second primary lung cancer (SPLC), which is associated with a poor ...

Symptoms and treatment options depend on the stage of your lung cancer along with what type of NSCLC you're diagnosed with. There are three primary types: adenocarcinoma, squamous cell carcinoma, and ...

A computed tomography (CT) scan may be needed ... for the group of cancerous cells to double in size) for small cell lung cancer varied from 38 to 217 days. Another study of those with squamous cell ...

To understand these complex interactions, we measure the density of different cell types in the stroma using immunohistochemistry techniques on tumor samples from lung cancer patients. We incorporate ...

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Squamous Non-Small Cell Lung ...